Cell penetrating peptide helps in delivery of large biomolecules such as peptides, proteins, and oligonucleotides inside cells. These peptides helps in enhancing bioavailability and effectiveness of various drugs used in treatment of cancer, cardiovascular diseases, ophthalmic diseases, and other therapeutic areas. The global Cell penetrating peptide Market is estimated to be valued at US$ 3.42 billion in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2024-2031, as highlighted in a new report published by Coherent Market Insights.
Market Opportunity:
The opportunity in targeted drug delivery holds potential for growth of cell penetrating peptide market. Targeted drug delivery helps in reducing side effects associated with conventional drugs by delivering the drug molecules only to diseased cells and tissues, leaving healthy cells unaffected. Cell penetrating peptides helps in achieving targeted delivery of therapeutic molecules to desired tissues thus overcoming limitations of conventional drug delivery techniques. The ability of cell penetrating peptides to facilitate targeted delivery of large molecules makes them suitable for delivery of biologics, peptides and nucleic acids which otherwise cannot cross cell membranes. This drives their increasing adoption in development of novel therapies for cancer and other diseases thereby presenting lucrative growth opportunities for cell penetrating peptide market over the forecast period.
Porter's Analysis
Threat of new entrants: The threat of new entrants is moderate as establishing a plant for manufacturing CPPS requires high capital investment in R&D as well as manufacturing infrastructure. Bargaining power of buyers: The bargaining power of buyers is high due to the presence of substitute products for CPPs in the drug delivery market. Bargaining power of suppliers: The bargaining power of suppliers is moderate as some key raw materials used for synthesizing CPPS have limited sources of production. Threat of new substitutes: The threat of new substitutes is high with the ongoing R&D in the areas of nanotechnology and advanced drug delivery mechanisms. Competitive rivalry: The competitive rivalry is high due to the presence of some major globally operating players.
SWOT Analysis
Strengths: High penetration ability, biocompatibility, non-immunogenicity and ability to deliver wide range of cargo molecules make CPPs an attractive drug delivery system. Weaknesses: Lack of tissue specificity and inability to control intracellular trafficking are the major weaknesses of CPPs. Opportunities: Wide scope of applications in areas of gene therapy, cancer treatment, protein/peptide therapeutics delivery presents significant growth opportunities. Threats: Biosafety issues and relatively high production costs are major threats challenging the widespread adoption of CPPs.
Key Takeaways
The Global Cell Penetrating Peptide Market Growth is expected to witness high at a CAGR of 16% during the forecast period of 2024 to 2031.The market size for cell penetrating peptides is projected to reach US$ 3.42 Bn by 2024.
Regional analysis: North America dominates the global CPP market currently due to presence of major research institutes and pharmaceutical companies. Asia Pacific region is expected to witness the highest growth rate during the forecast period with increasing R&D investments and outsourcing of clinical trials to countries like China and India.
Key players operating in the global Cell Penetrating Peptide market are AnaSpec, Peptomyc, BioAlps, Sarepta Therapeutics, Inc., REVANCE THERAPEUTICS, PolyPeptide Group, Bachem, Pepscan Creative Peptides, Cupidpeptides and AltaBioscience Ltd
Explore more information on this topic, Please visit-
Explore more trending article on this topic:
